Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis
Abdel-Rahman O, ElHalawani H, Ahmed H.
J Glob Oncol. 2015 Nov 25;1(2):73-82. doi: 10.1200/JGO.2015.000802. eCollection 2015 Dec.
CARDIONCOLOGY.ORG ABSTRACT:
This article describes a meta-analysis of the risk of cardiovascular toxicities associated with MEK inhibitors.
The data demonstrate that MEK inhibitor-based treatment is associated with an increased risk of all-grade and high-grade hypertension and asymptomatic decrease in ejection fraction.
© All rights reserved
image source: https://www.fiercebiotech.com/research/pd-1-mek-inhibitor-and-anti-cancer-virus-a-3-pronged-attack-melanoma